
Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population. hubs.li/Q04FFDn40

Your source for biopharma news and jobs

Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population. hubs.li/Q04FFDn40

New Updates - BioSpace's IPO dashboard helps the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026. hubs.li/Q04FFd6M0

Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” according to one biotech consultant. hubs.li/Q04FFcGn0

The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting PD-1/VEGF developers on notice; Isomorphic raised a $5B series C, largest in biotech history; ObesityWeek & Clinical Trials on Alzheimer’s Disease conferences underway. hubs.li/Q04FFc4J0

Your previous employer may have set a high standard. Executive coach Angela Justice explains how holding every company to it can distort your judgment and undermine your influence. hubs.li/Q04FF87F0

The Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators. hubs.li/Q04FF7jS0

AstraZeneca has cut about 600 U.S. commercial jobs, while Calidi Biotherapeutics plans to reduce its workforce by about 67%. Charles River Laboratories is closing its Worcester site, affecting two jobs, and Tempest Therapeutics is down to one employee. hubs.li/Q04FxDBR0

After securing $2.1 billion this May, AI-driven drug designer Isomorphic Labs is back with more money—a lot more—securing the industry’s largest private fundraise ever. hubs.li/Q04Fxzst0

Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals. hubs.li/Q04FwvVr0

At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease. hubs.li/Q04Fv_gF0

Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia. hubs.li/Q04FvR120

A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio. hubs.li/Q04FvLXP0

It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million. hubs.li/Q04FtYMD0

Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells. hubs.li/Q04FtYyG0

Women held 29% of biotech board seats in fiscal 2025 but just 8.8% of CEO roles, highlighting uneven progress across industry leadership spots. hubs.li/Q04FtYfC0

Helus Pharma’s psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events. hubs.li/Q04FmGJ60